Overview

Cholinergic Urticaria - Efficacy of Dupilumab

Status:
Unknown status

Trial end date:
2021-05-01

Target enrollment:

Participant gender:

Summary

The purpose of this study is to assess the efficacy in reducing disease activity and safety of Dupilumab in adult patients with cholinergic urticarial (CholU) who are symptomatic despite H1-antihistamine treatment (licensed dose).

Phase:

Phase 2

Details

Lead Sponsor:

Charite University, Berlin, Germany

Collaborator:

Sanofi

Treatments:

Antibodies, Monoclonal
Cholinergic Agents